INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE-FINDING STUDY TO DETERMINE THE SAFETY, EFFICACY, AND TOLERABILITY OF SOTATERCEPT (ACE-011) IN ADULTS WITH BETA-THALASSEMIA

被引：0
|
作者：
Porter, J. [1 ]
Cappellini, M. D. [2 ]
Origa, R. [3 ]
Forni, G. L. [4 ]
Laadem, A. [5 ]
Galacteros, F. [6 ]
Voskaridou, E. [7 ]
Miteva, D. [5 ]
Sung, V. [5 ]
Chopra, R. [5 ]
Arlet, J. B. [8 ]
Ribeil, J. A. [8 ]
Klesczewski, K. [5 ]
Attie, K. [9 ]
Garbowski, M. [1 ]
Graziadei, G. [2 ]
Balocco, M. [4 ]
Hermine, O. [8 ]
机构：
[1] UCL, London, England
[2] Univ Milan, Ca Granda Fdn IRCCS, Milan, Italy
[3] Univ Cagliari, Osped Reg Microcitemie, Cagliari, Italy
[4] Ente Osped Osped Galliera, Genoa, Italy
[5] Celgene Corp, Summit, NJ USA
[6] Grp Hosp Henri Mondor, Creteil, France
[7] Laikon Gen Hosp, Athens, Greece
[8] Hop Necker Enfants Malad, Inst Imagine, Paris, France
[9] Acceleron Pharma, Cambridge, MA 02139 USA
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S662
引用
收藏
页码：230 / 230
页数：1
相关论文
共 50 条
  • [41] A phase I/Ib, open-label, dose-finding study to evaluate safety, pharmacodynamics, and efficacy of pembrolizumab (MK-3475) in combination with vorinostat in patients with advanced renal or urothelial cell carcinoma
    Pili, Roberto
    Quinn, David
    Hahn, Noah M.
    Albany, Costantine
    Logan, Theodore F.
    Drake, Charles G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] A PHASE 1/2, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF BMN 110 IN SUBJECTS WITH MUCOPOLYSACCHARIDOSIS IVA (MORQUIO SYNDROME)
    Hendriksz, C.
    Vellodi, A.
    Jones, S.
    Capponi, M.
    Decker, C.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2010, 33 : S143 - S143
  • [43] Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study
    Chawla, Sant
    Henshaw, Robert
    Seeger, Leanne
    Choy, Edwin
    Blay, Jean-Yves
    Ferrari, Stefano
    Kroep, Judith
    Grimer, Robert
    Reichardt, Peter
    Rutkowski, Piotr
    Schuetze, Scott
    Skubitz, Keith
    Staddon, Arthur
    Thomas, David
    Qian, Yi
    Jacobs, Ira
    LANCET ONCOLOGY, 2013, 14 (09): : 901 - 908
  • [44] IncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study
    Christina Marciniak
    Michael C. Munin
    Allison Brashear
    Bruce S. Rubin
    Atul T. Patel
    Jaroslaw Slawek
    Angelika Hanschmann
    Reinhard Hiersemenzel
    Elie P. Elovic
    Advances in Therapy, 2019, 36 : 187 - 199
  • [45] IncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study
    Marciniak, Christina
    Munin, Michael C.
    Brashear, Allison
    Rubin, Bruce S.
    Patel, Atul T.
    Slawek, Jaroslaw
    Hanschmann, Angelika
    Hiersemenzel, Reinhard
    Elovic, Elie P.
    ADVANCES IN THERAPY, 2019, 36 (01) : 187 - 199
  • [46] Bimekizumab Long-Term Efficacy and Safety over 96 Weeks in Patients with Ankylosing Spondylitis: Interim Results from a Phase 2b Open-Label Extension Study
    Baraliakos, Xenofon
    Deodhar, Atul
    Dougados, Maxime
    Oortgiesen, Marga
    de Peyrecave, Natasha
    Bauer, Martin
    Vaux, Thomas
    Fleurinck, Carmen
    van der Heijde, Desiree
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [47] Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: A 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease
    Besarab, Anatole
    Salifu, Moro O.
    Lunde, N. Martin
    Bansal, Vinod
    Fishbane, Steven
    Dougherty, Frank C.
    Beyer, Ulrich
    CLINICAL THERAPEUTICS, 2007, 29 (04) : 626 - 639
  • [48] Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study
    Sidonio, Robert F.
    Thompson, Alexis A.
    Peyvandi, Flora
    Stasyshyn, Oleksandra
    Yeoh, Seoh Leng
    Sosothikul, Darintr
    Antmen, Ali Bulent
    Maggiore, Caterina
    Engl, Werner
    Ewenstein, Bruce
    Tangada, Srilatha
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (10) : 793 - 801
  • [49] Consistent safety and tolerability of Valtoco(R) (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: Interim results from a phase 3, long-term, open-label, repeat-dose safety study
    Miller, Ian
    Wheless, James W.
    Hogan, Robert E.
    Dlugos, Dennis
    Biton, Victor
    Cascino, Gregory D.
    Sperling, Michael R.
    Liow, Kore
    Vazquez, Blanca
    Segal, Eric B.
    Tarquinio, Daniel
    Mauney, Weldon
    Desai, Jay
    Rabinowicz, Adrian L.
    Carrazana, Enrique
    EPILEPSIA OPEN, 2021, 6 (03) : 504 - 512
  • [50] Interim results from a phase 2, open-label study evaluating an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in wolfram syndrome (HELIOS)
    Urano, F.
    Hurst, S.
    Marshall, B.
    Erpelding, N.
    Cottrell, K.
    Leinders, M.
    Mehta, L.
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 : 50 - 50
12345